EURURO Vol. 72 No. 6

971 1030

consulting or advisory fees from Novartis, Eisai, and Pfizer, and research
funding from Exelixis, Bristol-Myers Squibb, Novartis, GlaxoSmithKline,
Eisai, and Pfizer. Katrina Peltola has received advisory fees from MSD,
Bristol-Myers Squibb, Lilly, Sanofi, Astellas, Pfizer, and Novartis, and travel
compensation from Pierre[9_TD$DIFF] Fabre and Bristol-Myers Squibb. Elizabeth
Plimack has received consulting or advisory fees from Merck, Dendreon,
Novartis, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Acceleron
Pharma, and Genentech/Roche, and institutional research funding from
Merck, Bristol-Myers Squibb, GlaxoSmithKline, Acceleron Pharma,
Dendreon, Lilly, and AstraZeneca, and has an institutional interest in
US Patent No. 14/588.503. [10_TD$DIFF]Giuseppe Procopio has received grants from
Bayer and personal fees from Astellas, Bristol-Myers Squibb, Janssen,
Novartis, and Pfizer. Padmanee Sharma has received leadership fees from
Kite Pharma, Jounce, and Evelo; consultant or advisor fees from Bristol-
Myers Squibb, GlaxoSmithKline, AstraZeneca, and Amgen; investigator
fees from Bristol-Myers Squibb, GlaxoSmithKline, and AstraZeneca. She
has investment interests in Jounce, Kite Pharma, Evelo, and owns a patent
licensed to Jounce. Her spouse has received leadership fees from Kite
Pharma, Jounce, and Neon; has investment interests in Jounce, Kite, and
Neon; and has an interest in patents licensed to Bristol-Myers Squibb,
Jounce, and Merck. Jeffrey Sosman has received honoraria and consulting
or advisory fees fromNovartis, Genentech, Array, andMerck; and research
funding from [11_TD$DIFF]Bristol-Myers Squibb, Biomedical Valley Development, and
GlaxoSmithKline. Scott Tykodi has received consulting or advisory fees
from Prometheus Laboratories and Amgen, and institutional research
funding from Genentech, Bristol-Myers Squibb, Exelixis, Argos Therapeu-
tics, GlaxoSmithKline, and Prometheus. An immediate family member of
John Wagstaff has received honoraria from Roche, Bristol[12_TD$DIFF]-Myers[13_TD$DIFF] Squibb,
Pfizer, Novartis, andMSD; consulting or advisory fees fromRoche, Bristol[12_TD$DIFF]-
Myers[13_TD$DIFF] Squibb, Pfizer, Novartis, and MSD; and travel and [14_TD$DIFF]accommodation
expenses from Bristol-Myers Squibb and MSD. Ian Waxman and Huanyu
Zhao are employed by and hold stock in Bristol-Myers Squibb. Daniel
Castellano, Sandhya Srinivas, and Takeshi Ueda have nothing to disclose.
Funding/Support and role of the sponsor: This study was sponsored by
Bristol-Myers Squibb and Ono Pharmaceutical Company Limited. The
sponsors contributed to the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, and approval of the manuscript in collaboration with the
investigators and authors of this report.
Acknowledgments: We thank the patients and their families, as well as
the investigators and participating study teams, for making this study
possible. Medical writing assistance was provided by Jennifer Granit of
PPSI (a PAREXEL company) and was funded by Bristol-Myers Squibb.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
.
References
[1]
.
[2]
.
[3]
[4]
.
[5]
[6]
[7]
.
[8] Opdivo (nivolumab) injection [prescribing information]. Princeton,
NJ: Bristol-Myers Squibb; 2015.
[9]
.
[10]
[11]
[12]
.
[13]
[14]
.
[15]
.
[16]
.
[17]
[18]
.
[19]
.
[20]
[21] National Comprehensive Cancer Network. NCCN clinical practice
guidelines in oncology: kidney cancer. Version 2.2016.
[22]
.
[23]
[24]
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 9 6 2 – 9 7 1 971